TrialInvestigational new drugs2014

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Anna Spreafico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.